"The risk of GBS tends to go up, it's another one of those risks that tends to go up, with age. But there's nothing to indicate that there's any particular risk of GBS," he said. The CDC panel is also expected to weigh the possibility of whether and when adults will need to ...
Risks of RSV in Older Adults With Chronic Conditions RSV mostly affects children under 2, but it can be serious in adults over 65 who are immunocompromised or have chronic conditions. Here’s why. “No vaccine is 100 percent effective. An 80 percent vaccine effectiveness rate is quite impressi...
Adding a new precaution for the older chikungunya vaccine that uses weakened but live virus: People 65 and older should weigh the risks of benefits of that version of the shot, the panel said. The precaution was added after panel members heard about an investigation into six reports of people...
5. Healthcare providers: RSV vaccination for adults 60 years of age and over. CDC. Updated March 1, 2024. Accessed April 4, 2024. https://www.cdc.gov/vaccines/vpd/rsv/hcp/older-adults.html 6. US FDA approves GSK’s Arexvy, the world’s first respiratory syncytial virus (RSV...
The first real-world study highlights benefits for adults aged 60 years and older who receive the respiratory syncytial virus (RSV) vaccine. August 31st 2024 Sixty Percent of Adults Over 50 Unaware of RSV Risks, Survey Reveals Pearl Steinzor ...
The new guidance stops short of a full-throated recommendation for all eligible older adults to get the shots. Instead, the panel called for"shared clinical decision-making"between doctors and patients to decide whether the individual benefits outweigh the risks. ...
Ground-breaking approval enables adults aged 60 years and older to be protected from RSV disease for the first time The approval is based on data from the positive pivotal AReSVi-006 phase III trial that showed exceptional efficacy in older adults, including th...
are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include but are not limited to those described under Item 3.D 'Risk factors” in the company's Annual Report on Form 20-F for 2022, GSK’s Q1 Results for 2023 and...
-- GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has accepted under Priority Review an application to extend the indication of GSK’s adjuvanted respiratory syncytial virus (RSV) vaccine to ad...
GSK plc (LSE/NYSE: GSK) today announced positive preliminary results from its phase III trial [NCT05590403] evaluating the immune response and safety of AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) in adults aged 50 to 59,...